Literature DB >> 32651697

Prognostic Factors for Surgically Resected Intraductal Papillary Neoplasm of the Bile Duct: A Retrospective Cohort Study.

Shuichiro Uemura1, Ryota Higuchi2, Takehisa Yazawa1, Wataru Izumo1, Yutaro Matsunaga1, Masahiro Shiihara1, Takehiro Ota1, Toru Furukawa3, Masakazu Yamamoto1.   

Abstract

BACKGROUND: To date, postoperative prognostic factors for intraductal papillary neoplasm of the bile duct (IPNB) have not been well-established. This study aimed to examine the histopathologic features and postoperative prognosis of the two IPNB subclassifications, as well as factors affecting prognosis, based on the authors' experience at a single institution.
METHODS: The study enrolled 83 patients who underwent surgical resection for pathologically diagnosed IPNB at the authors' institution. The clinicopathologic features and postoperative outcomes for these patients were examined. The study also investigated postoperative prognostic factors for IPNB using uni- and multivariate analyses.
RESULTS: More than half of the tumors (64%) diagnosed as IPNB were early-stage cancer (UICC Tis or T1). However, none were diagnosed as benign. The multivariate analysis showed that lymph node metastasis (hazard ratio [HR], 5.78; p = 0.002) and bile duct margin status with carcinoma in situ (D-CIS; HR, 5.10; p = 0.002) were independent prognostic factors, whereas MUC6 expression showed only a marginal influence on prediction of prognosis (HR, 0.32; p = 0.07). The tumor recurrence rate and the proportion of locoregional recurrence were significantly greater among the patients with D-CIS than among those with negative bile duct margins, including those patients with low-grade dysplasia. The patients with D-CIS showed a significantly poorer prognosis than those with negative bile duct margins (5-year survival, 38% versus 87%; p = 0.0002).
CONCLUSIONS: Evaluation of resected IPNBs showed cancer in all cases. Avoiding positive biliary stumps during surgery, including resection of carcinoma in situ, would improve the prognosis for patients with IPNB.

Entities:  

Mesh:

Year:  2020        PMID: 32651697     DOI: 10.1245/s10434-020-08835-6

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  25 in total

1.  Targeted next-generation sequencing identifies distinct clinicopathologic and molecular entities of intraductal papillary neoplasms of the bile duct.

Authors:  Ching-Yao Yang; Wei-Ju Huang; Jia-Huei Tsai; Arkady Cheng; Chih-Chi Chen; Hung-Pin Hsu; Yung-Ming Jeng
Journal:  Mod Pathol       Date:  2019-06-23       Impact factor: 7.842

Review 2.  A statement by the Japan-Korea expert pathologists for future clinicopathological and molecular analyses toward consensus building of intraductal papillary neoplasm of the bile duct through several opinions at the present stage.

Authors:  Yasuni Nakanuma; Kee-Taek Jang; Noriyoshi Fukushima; Toru Furukawa; Seung-Mo Hong; Haeryoung Kim; Kyung Bun Lee; Yoh Zen; Jin-Young Jang; Keiichi Kubota
Journal:  J Hepatobiliary Pancreat Sci       Date:  2018-02-12       Impact factor: 7.027

3.  Biliary papillary tumors share pathological features with intraductal papillary mucinous neoplasm of the pancreas.

Authors:  Yoh Zen; Takahiko Fujii; Keita Itatsu; Koichi Nakamura; Hiroshi Minato; Satomi Kasashima; Hiroshi Kurumaya; Kazuyoshi Katayanagi; Atsuhiro Kawashima; Shinji Masuda; Hideki Niwa; Takeshi Mitsui; Yasuyuki Asada; Shouji Miura; Tetsuo Ohta; Yasuni Nakanuma
Journal:  Hepatology       Date:  2006-11       Impact factor: 17.425

4.  Intraductal papillary neoplasm of the bile duct: a biliary equivalent to intraductal papillary mucinous neoplasm of the pancreas?

Authors:  Flavio G Rocha; Hwajeong Lee; Nora Katabi; Ronald P DeMatteo; Yuman Fong; Michael I D'Angelica; Peter J Allen; David S Klimstra; William R Jarnagin
Journal:  Hepatology       Date:  2012-08-27       Impact factor: 17.425

5.  A comparative study of intraductal papillary neoplasia of the biliary tract and pancreas.

Authors:  Jaap J Kloek; Niels A van der Gaag; Deha Erdogan; Erik A J Rauws; Olivier R C Busch; Dirk J Gouma; Fiebo J W ten Kate; Thomas M van Gulik
Journal:  Hum Pathol       Date:  2011-02-02       Impact factor: 3.466

6.  Long-term clinical outcome of the surgically resected intraductal papillary neoplasm of the bile duct.

Authors:  Geunyoung Jung; Kwang-Min Park; Seung Soo Lee; Eunsil Yu; Seung-Mo Hong; Jihun Kim
Journal:  J Hepatol       Date:  2012-05-23       Impact factor: 25.083

7.  Biliary cystic tumors with bile duct communication: a cystic variant of intraductal papillary neoplasm of the bile duct.

Authors:  Yoh Zen; Takahiko Fujii; Keita Itatsu; Koichi Nakamura; Fumio Konishi; Shinji Masuda; Takeshi Mitsui; Yasuyuki Asada; Shouji Miura; Shiro Miyayama; Takeshi Uehara; Tsutomu Katsuyama; Tetsuo Ohta; Hiroshi Minato; Yasuni Nakanuma
Journal:  Mod Pathol       Date:  2006-06-02       Impact factor: 7.842

8.  Intraductal papillary neoplasia of the liver associated with hepatolithiasis.

Authors:  T C Chen; Y Nakanuma; Y Zen; M F Chen; Y Y Jan; T S Yeh; C T Chiu; T T Kuo; J Kamiya; K Oda; M Hamaguchi; Y Ohno; L L Hsieh; Y Nimura
Journal:  Hepatology       Date:  2001-10       Impact factor: 17.425

9.  Impact of macroscopic morphology, multifocality, and mucin secretion on survival outcome of intraductal papillary neoplasm of the bile duct.

Authors:  Mee Joo Kang; Jin-Young Jang; Kyoung Bun Lee; In Woong Han; Sun-Whe Kim
Journal:  J Gastrointest Surg       Date:  2013-01-31       Impact factor: 3.452

Review 10.  Systematic Review and Meta-analysis of Current Experience in Treating IPNB: Clinical and Pathological Correlates.

Authors:  Alex N Gordon-Weeks; Keaton Jones; Elinor Harriss; Adrian Smith; Michael Silva
Journal:  Ann Surg       Date:  2016-04       Impact factor: 12.969

View more
  1 in total

1.  Clinical characteristics of intrahepatic biliary papilloma: A case report.

Authors:  Dan Yi; Li-Jing Zhao; Xiao-Bo Ding; Tai-Wei Wang; Song-Yang Liu
Journal:  World J Clin Cases       Date:  2021-05-06       Impact factor: 1.337

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.